HIV and AIDS
 

Dyslipidemia (Lipid Abnormalties)


Switching from Efavirenz (Sustiva) to Nevirapine (Viramune) Decreases LDL Cholesterol Levels in Patients with Dyslipidemia    - 7/10/07

High Dietary Fat Consumption Is Associated with Elevated Serum Lipids in HIV Positive Individuals  - 3/16/07

Role of Traditional Risk Factors vs HAART in the Development of Metabolic Syndrome   - 2/09/07

Pravastatin, Ezetimibe, and Acipimox in the Management of Metabolic Complications in People with HIV  12/12/06

Switching from Efavirenz to Nevirapine Resolves Neuropsychiatric Symptoms and Improves Lipid Profiles   12/08/06

Atazanavir Has a Positive Effect on Blood Lipid Profiles   12/01/06

NRTI-sparing Atazanavir/Efavirenz Regimens Suppress HIV but Raise Lipids   10/03/06

Impact of Boosted vs Unboosted Atazanavir-based Regimens on the Lipid Profiles of HIV Positive Patients - 8/29/06

Pravastatin and Bezafibrate Show Greater Effectiveness in Reducing Lipid Elevations Than Switching Therapy from a Protease Inhibitor to Nevirapine or Efavirenz - 6/20/05

Lopinavir/ritonavir Combination and Total/HDL Cholesterol Ratio - 4/04/05

Lipid Disorders in Treatment-naive HIV Patients Using Lopinavir/Ritonavir-based HAART - 3/25/05

Dyslipidemia Significantly Increases Cardiac Risk in HAART Patients - 3/16/05

Data at 12th CROI Builds Optimism on Metabolic and Morphologic Management - 3/11/05

Efavirenz with Two Nucleoside Analogs Is Superior for Regimen Simplification  - 2/28/05

Treatment with Pioglitazone But Not  with Fenofibrate Improves HAART-related Metabolic Syndrome   - 2/14/05

A Comparison of Dyslipidemias Associated with Either Lopinavir/Ritonavir- or Indinavir/Ritonavir-based Antiretroviral Therapy - 2/11/05

Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-sparing Approach in Treatment-experienced HIV Patients - 1/12/05

Dyslipidemias
•  Characteristics
•  Increased Risk of Cardiovascular Disease in HIV
•  Evaluation of Serum Lipids
•  Idications for Intervention – Hypercholesterolemia
•  Indications for Intervention – Hypertriglyceridemia
•  Management Approaches
•  Drug Therapies
•  HMG-CoA Reductase Inhibitors (Statins)
•  Fibrates
•  Antiretroviral Switching Strategies
•  Summary and Conclusions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

HIV AND AIDS | HEPATITIS B | HEPATITIS C | HIV / HBV CO-INFECTION | HIV / HCV CO-INFECTION | HEALTH AND TECHNOLOGY | TESTS | INTERNET CONFERENCE REPORTS | TELECONFERENCES | LINKS | ABOUT US | CONTACT US